LAPATINIB DITOSYLATE | NOVARTIS | ||
EQ 250MG BASE | |||
Yes | No | ||
2029-Sep-18 | 2012-Mar-13 | ||
None | None | ||
None | No | ||
TYKERB is a kinase inhibitor indicated in combination with: • capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. • letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. |
2 | 0 | 2 |
Total Other Developers | 1 |
---|
Drugs with Suitability | No |
---|
EQ 250MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 1 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|---|---|---|---|---|
****** | ***** ****** *** | ***** ****** ******* | *********** | ****** ********, ******, **********, ********* *** ***, ***** (***) | *** |
****** | ***** ****** *** | ***** ****** ******* | *********** | **** **.: ** & **, ****, ***** ****** ****, ********, *************, ****** ******* ******, ***** (***) | *** |
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com